Skip to main content
SpringerLink
Log in

Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population

  • Published:
Journal of Zhejiang University SCIENCE B Aims and scope Submit manuscript

Abstract

Objective

The aim of this study was to evaluate the association between the methylenetetrahydrofolate reductase (MTHFR) C677T excision repair cross-complementation group 1 (ERCC1) genetic polymorphisms and the clinical efficacy of gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).

Methods

A total of 135 chemonaive patients with unresectable advanced NSCLC were treated with gemcitabine/platinum regimens. The polymorphisms of MTHFR C677T, ERCC1 C8092A, and ERCC1 C118T were genotyped using the TaqMan methods.

Results

The overall response rate was 28.9%. Patients with MTHFR CC genotype had a higher rate of objective response than patients with variant genotype (TT or CT) (41.2% versus 19.1%, P=0.01). Median time to progression (TTP) of patients with MTHFR CC genotype was longer than that of patients with variant genotype (7.6 months versus 5.0 months, P=0.003). No significant associations were obtained between ERCC1 C118T and C8092A polymorphisms and both response and survival.

Conclusions

Our data suggest the value of MTHFR C677T polymorphism as a possible predictive marker of response and TTP in advanced NSCLC patients treated with gemcitabine/platinum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Alberola, V., Sarries, C., Rosell, R., Taron, M., de las Peñas, R., Camps, C., Massuti, B., Insa, A., Garcia-Gomez, R., Isla, D., et al., 2004. Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer. Clin. Lung Cancer, 5(6):360–365. [doi:10.3816/CLC.2004.n.014]

    Article  PubMed  CAS  Google Scholar 

  • Azzoli, C.G., Baker, S.J., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D.H., Laskin, J.L., Masters, G., Milton, D., et al., 2009. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol., 27(36):6251–6262. [doi:10.1200/JCO.2009.23. 5622]

    Article  PubMed  CAS  Google Scholar 

  • Chen, P., Wiencke, J., Aldape, K., Kesler-Diaz, A., Miike, R., Kelsey, K., Lee, M., Liu, J., Wrensch, M., 2000. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol. Biomark Prev., 9(8):843–847.

    CAS  Google Scholar 

  • Choi, S.W., Mason, J.B., 2000. Folate and carcinogenesis: an integrated scheme. J. Nutr., 130(2):129–132.

    PubMed  CAS  Google Scholar 

  • Choi, S.W., Mason, J.B., 2002. Folate status: effects on pathways of colorectal carcinogenesis. J. Nutr., 132(S8): 2413S–2418S.

    PubMed  CAS  Google Scholar 

  • Cohen, V., Panet-Raymond, V., Sabbaghian, N., Morin, I., Batist, G., Rozen, R., 2003. Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin. Cancer Res., 9(5): 1611–1615.

    PubMed  CAS  Google Scholar 

  • D’Angelo, V., Ramaglia, M., Iannotta, A., Crisci, S., Indolfi, P., Francese, M., Affinita, M.C., Pecoraro, G., Napolitano, A., Fusco, C., et al., 2011. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother. Pharmacol., 68(5):1339–1346. [doi:10.1007/s00280-011-1665-1]

    Article  PubMed  Google Scholar 

  • de las Peñas, R., Sanchez-Ronco, M., Alberola, V., Taron, M., Camps, C., Garcia-Carbonero, R., Massuti, B., Queralt, C., Botia, M., Garcia-Gomez, R., et al., 2006. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small cell lung cancer patients. Ann. Oncol., 17(4):668–675. [doi:10.1093/annonc/mdj135]

    Article  PubMed  Google Scholar 

  • Etienne-Grimaldi, M.C., Milano, G., Maindrault-Goebel, F., Chibaudel, B., Formento, J.L., Francoual, M., Lledo, G., André, T., Mabro, M., Mineur, L., et al., 2010. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. Br. J. Clin. Pharmacol., 69(1):58–66. [doi:10.1111/j.1365-2125.2009.03556.x]

    Article  PubMed  CAS  Google Scholar 

  • Fernández-Peralta, A.M., Daimiel, L., Nejda, N., Iglesias, D., Medina, A.V., González-Aguilera, J.J., 2010. Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy. Int. J. Colorectal. Dis., 25(2):141–151. [doi:10.1007/s00384-009-0779-y]

    Article  PubMed  Google Scholar 

  • Gandara, D.R., Kawaguchi, T., Crowley, J., Moon, J., Furuse, K., Kawahara, M., Teramukai, S., Ohe, Y., Kubota, K., Williamson, S.K., et al., 2009. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J. Clin. Oncol., 27(21):3540–3546. [doi:10.1200/JCO.2008.20.8793]

    Article  PubMed  CAS  Google Scholar 

  • Guilbert, J.J., 2003. The world health report 2002—reducing risks, promoting healthy life. Educ. Health (Abingdon), 16(2):230–233.

    Article  CAS  Google Scholar 

  • Isla, D., Sarries, C., Rosell, R., Alonso, G., Domine, M., Taron, M., Lopez-Vivanco, G., Camps, C., Botia, M., Nuñez, L., et al., 2004. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol., 15(8):1194–1203. [doi:10.1093/annonc/mdh319]

    Article  PubMed  CAS  Google Scholar 

  • Kalikaki, A., Kanaki, M., Vassalou, H., Souglakos, J., Voutsina, A., Georgoulias, V., Mavroudis, D., 2009. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin. Lung Cancer, 10(2):118–123. [doi:10.3816/CLC. 2009.n.015]

    Article  PubMed  CAS  Google Scholar 

  • Kim, H.N., Kim, Y.K., Lee, I.K., Yang, D.H., Lee, J.J., Shin, M.H., Park, K.S., Choi, J.S., Park, M.R., Jo, D.Y., et al., 2009. Association between polymorphisms of folate-metabolizing enzymes and hematological malignancies. Leuk. Res., 33(1):82–87. [doi:10.1016/j.leukres.2008. 07.026]

    Article  PubMed  CAS  Google Scholar 

  • Kim, Y.I., 1999. Folate and carcinogenesis: evidence, mechanisms, and implications. J. Nutr. Biochem., 10(2):66–88. [doi:10.1016/S0955-2863(98)00074-6]

    Article  PubMed  CAS  Google Scholar 

  • le Chevalier, T., Scagliotti, G., Natale, R., Danson, S., Rosell, R., Stahel, R., Thomas, P., Rudd, R.M., Vansteenkiste, J., Thatcher, N., et al., 2005. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer, 47(1):69–80. [doi:10.1016/j.lungcan.2004.10.014]

    Article  PubMed  Google Scholar 

  • Li, F., Sun, X., Sun, N., Qin, S., Cheng, H., Feng, J., Chen, B., Cheng, L., Lu, Z., Ji, J., et al., 2010. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am. J. Clin. Oncol., 33(5):489–494. [doi:10.1097/COC.0b013e3181b9cedc]

    Article  PubMed  CAS  Google Scholar 

  • Park, D.J., Zhang, W., Stoehlmacher, J., Tsao-Wei, D., Groshen, S., Gil, J., Yun, J., Sones, E., Mallik, N., Lenz, H.J., 2002. ERCC1 Polymorphism is Associated with Differential ERCC1 Gene Expression. ASCO Proceedings. American Association for Cancer Research, San Francisco, CA, p.1591.

    Google Scholar 

  • Reed, E., Dabholkar, M., Thornton, K., Thompson, C., Yu, J.J., Bostick-Bruton, F., 2000. Evidence for order in the appearance of mRNAs of nucleotide excision repair genes in human ovarian cancer tissues. Oncol. Rep., 7: 1123–1128.

    PubMed  CAS  Google Scholar 

  • Ryu, J.S., Hong, Y.C., Han, H.S., Lee, J.E., Kim, S., Park, Y.M., Kim, Y.C., Hwang, T.S., 2004. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer, 44(3):311–316. [doi:10.1016/j.lungcan.2003.11.019]

    Article  PubMed  Google Scholar 

  • Salazar, J., Altés, A., Del Río, E., Estella, J., Rives, S., Tasso, M., Navajas, A., Molina, J., Villa, M., Vivanco, J.L., et al., 2011. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmacogenomics J., 12(5):379–385. [doi:10.1038/tpj. 2011.25]

    Article  PubMed  Google Scholar 

  • Smit, E.F., Burgers, S.A., Biesma, B., Smit, H.J., Eppinga, P., Dingemans, A.M., Joerger, M., Schellens, J.H., Vincent, A., van Zandwijk, N., et al., 2009. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer. J. Clin. Oncol., 27(12):2038–2045. [doi:10.1200/JCO.2008.19.1650]

    Article  PubMed  CAS  Google Scholar 

  • Smith, S., Su, D., de la Longrais, I.A.R., Schwartz, P., Puopolo, M., Rutherford, T.J., Mor, G., Yu, H., Katsaros, D., 2007. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy. J. Clin. Oncol., 25(33):5172–5179. [doi:10.1200/JCO.2007.11. 8547]

    Article  PubMed  CAS  Google Scholar 

  • Spiro, S.G., Silvestri, G.A., 2005. The treatment of advanced non-small cell lung cancer. Curr. Opin. Pulm. Med., 11(4): 287–291. [doi:10.1097/01.mcp.0000166590.03042.56]

    Article  PubMed  CAS  Google Scholar 

  • Su, D., Ma, S., Liu, P., Jiang, Z., Lv, W., Zhang, Y., Deng, Q., Smith, S., Yu, H., 2007. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer, 56(2):281–288. [doi:10.1016/j.lungcan. 2006.12.002]

    Article  PubMed  Google Scholar 

  • Therasse, P., Arbuck, S.G., Eisenhauer, E.A., Wanders, J., Kaplan, R.S., Rubinstein, L., Verweij, J., van Glabbeke, M., van Oosterom, A.T., Christian, M.C., et al., 2000. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst., 92(3):205–216. [doi:10.1093/jnci/92.3.205]

    Article  PubMed  CAS  Google Scholar 

  • Tibaldi, C., Giovannetti, E., Vasile, E., Mey, V., Laan, A.C., Nannizzi, S., Di Marsico, R., Antonuzzo, A., Orlandini, C., Ricciardi, S., et al., 2008. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin treated advanced non-small cell lung cancer patients. Clin. Cancer Res., 14(6):1797–1803. [doi:10.1158/1078-0432.CCR-07-1364]

    Article  PubMed  CAS  Google Scholar 

  • Wang, J., Zhang, Q., Zhang, H., Wang, Q., Yang, X., Gu, Y., Zhang, S., 2010. Association between polymorphisms of ERCC1 and response in patients with advanced non-small cell lung cancer receiving cisplatin-based chemotherapy. Chin. J. Lung Cancer, 13(4):337–341 (in Chinese). [doi:10.3779/j.issn.1009-3419.2010.04.13]

    CAS  Google Scholar 

  • Xie, F.J., Zhao, P., Kou, J.Y., Hong, W., Fu, L., Hu, L., Hong, D., Su, D., Gao, Y., Zhang, Y.P., 2012. The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum. Cancer Chemother. Pharmacol., 69(6):1443–1448. [doi:10.1007/s00280-012-1849-3]

    Article  PubMed  CAS  Google Scholar 

  • Yin, M., Yan, J., Voutsina, A., Tibaldi, C., Christiani, D.C., Heist, R.S., Rosell, R., Booton, R., Wei, Q., 2011. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer, 72(3):370–377. [doi:10.1016/j.lungcan.2010.10.011]

    Article  PubMed  Google Scholar 

  • Yu, J.J., Lee, K.B., Mu, C., Li, Q., Abernathy, T.V., Bostick-Bruton, F., Reed, E., 2000. Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int. J. Oncol., 16:555–560.

    PubMed  CAS  Google Scholar 

  • Zhou, W., Gurubhagavatula, S., Liu, G., Park, S., Neuberg, D.S., Wain, J.C., Lynch, T.J., Su, L., Christiani, D.C., 2004. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced nonsmall cell lung cancer patients treated with platinum-based chemotherapy. Clin. Cancer Res., 10(15):4939–4943. [doi:10.1158/1078-0432.CCR-04-0247]

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022, China

    Wei Hong, Yi-ping Zhang, Dan Hong, Xin-min Yu & Fa-jun Xie

  2. Zhejiang Key Laboratory of the Diagnosis and Treatment Technology on Thoracic Oncology, Hangzhou, 310022, China

    Wei Hong, Yi-ping Zhang, Dan Hong, Dan Su, Wei-min Mao, Xin-min Yu & Fa-jun Xie

  3. Department of Respiratory Medicine, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310009, China

    Kai Wang

  4. Department of Medical Oncology, Hangzhou Cancer Hospital, Hangzhou, 310002, China

    Jun-yan Kou

  5. Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou, 310058, China

    Xiao-jian Wang

Authors
  1. Wei Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kai Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yi-ping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jun-yan Kou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dan Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dan Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wei-min Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xin-min Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Fa-jun Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xiao-jian Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yi-ping Zhang.

Additional information

The two authors contributed equally to this work

Project supported by the National Natural Science Foundation of China (No. 30900654), the Medical Scientific Research Foundation of Zhejiang Province (Nos. 2007B025, 2010KYA036, and 2010KYA 032), the Science and Technology Department of Zhejiang Province (Nos. 2011c23017 and 2012c23081), and the Zhejiang Major Science and Technology Special Project (No. 2009C13018), China

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hong, W., Wang, K., Zhang, Yp. et al. Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population. J. Zhejiang Univ. Sci. B 14, 207–215 (2013). https://doi.org/10.1631/jzus.B1200101

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1631/jzus.B1200101

Key words

CLC number

Search

Navigation